Loading…
← CockpitCompetitor Analysis › 6712.TWO Ever Supreme Bio Technology Co., Ltd.Open in the cockpit ↗

Ever Supreme Bio Technology Co., Ltd.6712.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Momentum strong 78
Mkt cap
$427M
US dollars, full cap
Free float
47%
of shares outstanding
$/day
$721,953
20-day average traded
Fwd P/E
26.2×
forward earnings
ROIC−WACC
+9.7 pp
WACC 5.0%
Hurdle
-65 pp
Req g minus delivered
Next earnings
120 days
18 Mar 2027
Close · TWDNT$142.00
1D0.0%
1W-4.0%
1M-9.6%
3M-3.4%
6M+10.9%
YTD-9.1%
1Y-7.4%
ATR %2.6%
52w lowhigh22.8% off high

What Ever Supreme Bio Technology does

No business profile yet.

Ever Supreme Bio Technology at a glance

Size Ever Supreme Bio Technology (6712.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $427M, the 480th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$142.00 on 18 Nov 2026.

Performance Over six months the shares gained 10.9%, against -22.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 13.3% over the last twelve months (peer median +1.7%); the operating margin is 46.9% (peer median -17.2%).

Valuation It trades at 26.2× forward earnings against a peer median of 33.9× (3rd cheapest of 6).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +71%, so the hurdle is -65 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 20266712.TWO 107Peer median 78
Six months, rebased to 100: Ever Supreme Bio Technology against the median of its 20 peers (local-currency closes).

Ever Supreme Bio Technology financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$1.14BNT$1.02BNT$889MNT$758MNT$628M
Revenue growth—+14%+17%+21%—
Gross profitNT$892MNT$711MNT$597MNT$466MNT$396M
EBITDAn/aNT$462MNT$452MNT$370MNT$319M
Net incomeNT$464MNT$429MNT$367MNT$539MNT$201M
Free cash flown/aNT$535MNT$435MNT$416MNT$316M
Capital expendituren/aNT$48.8MNT$46.2MNT$5.83MNT$8.11M
Total debtn/aNT$38.7MNT$2.84MNT$5.90MNT$17.9M

Quarterly statements and history in the cockpit →

Ever Supreme Bio Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-20%0%2509PRTA65476883171789476830CADL603739456160688163000710EPRXIRLA688238ARVN65896998337811671151806712.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Ever Supreme Bio Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×50×100×150×25096547178960373911676712.TWORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ever Supreme Bio Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%6883171789603739699811676712.TWOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ever Supreme Bio Technology is the large dot.

Ever Supreme Bio Technology competitors and peer comparison

How Ever Supreme Bio Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ever Supreme Bio Technology against its 20 peers (data as of 18 Nov 2026)
Measure6712.TWOPeer medianRank in peer set
1-month return-9.6%-13.4%9th highest of 21
6-month return+10.9%-22.5%3rd highest of 21
Distance from 52-week high-22.8%-46.2%highest of 21
Revenue growth (TTM)+13.3%+1.7%8th highest of 17
Operating margin46.9%-17.2%3rd highest of 17
Forward P/E26.2×33.9×3rd cheapest of 6
Growth the price implies (Req g, 7 yrs)5.3%-6.6%2nd most demanding of 7
Growth delivered (Del g)+70.5%+0.5%2nd highest of 6
Hurdle (Req g minus delivered)-65.2 pp+1.6 pp2nd least demanding of 6
ROIC minus cost of capital+9.7 pp-12.7 pp2nd highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%26.2×5.3%+70.5%
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%10.2×-19.5%n/a
Prothena PRTAUnited States$429M-11%+347%-73%n/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%170.0×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%n/a4.0%-62.3%
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%39.4×2.1%+0.5%
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%n/an/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%33.9×7.7%+7.3%
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%n/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%n/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%n/an/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%n/an/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%n/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%n/a-15.3%+197.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%5.7×-18.8%-36.1%
Qurient 115180.KSSouth Korea$452M-56%-14%-512%n/an/an/a

Questions

Which companies are Ever Supreme Bio Technology's closest peers?
The cockpit's peer set: Qyuns Therapeutics (2509.HK), Prothena (PRTA), Medigen Vaccine Biologics (6547.TWO), Shanghai ZJ Bio-Tech (688317.SS), Scinopharm Taiwan (1789.TW), Rznomics (476830.KS), Candel Therapeutics (CADL), Qingdao Vland Biotech (603739.SS).
Is Ever Supreme Bio Technology expensive compared with its peers?
On forward p/e it trades at 26.2× against a peer median of 33.9×, 3rd cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +71%, so the hurdle is -65 pp: the price already allows for a slowdown.
How has Ever Supreme Bio Technology stock performed?
Over six months to 18 Nov 2026 the shares returned +10.9% against -22.5% for the median peer; over one year -7.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.